digital pill

The pair will meet quarterly to discuss possible integrations and collaborations with the pharma industry. 

Also: Centauri Health Solutions acquires HCFS; UCSF researchers detail smartphone PPG-based diabetes detection.

The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.

The pharma company walks away with the full license for Proteus' mental health treatment adherence technology.

News of the ID-Cap System's 510(k) comes amidst reports of turmoil within the business of its predecessor in clearance, Proteus Digital Health.

The digital pill maker's employees were brought back after the company secured $5 million in emergency funding, but CNBC's report suggests that several are now looking elsewhere for work.

The independent investigation suggests that wirelessly observed therapies using Proteus' system could be considered equivalent to in-person medication adherence programs, but much better received by patients taking oral medications.

The sensor-embedded pill will be used to treat and monitor colorectal cancer patients receiving care at Fairview Health Services.

As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies.

The ingesitble sensors will let providers look at adherence habits, activity levels and resting heart rate within a younger patient population.